OBJECTIVE: To discuss the progress in the chemotherapy, radiotherapy, preventive radiotherapy of whole brain, targeted therapy etc. for small cell lung cancer (SCLC).

KRAS mutation frequency in tumor tissue, can be predicted non-small cell lung cancer molecular targeted therapy efficacy and prognosis, and molecular inhibitors of RAS genes is still in its infancy.

So these latest findings will help us work out how best to target them in small cell lung cancer.